Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen In Insulin Therapy

CHICAGO, June 24, 2007 – Novo Nordisk today announced results of a new study that further demonstrated the safety and efficacy of insulin Levemir® (insulin detemir [rDNA origin] injection). Patients with Type 2 diabetes were able to adjust their own dosage of Levemir® and achieve improvements in blood sugar, comparable to dosing adjusted by their primary care physician. This improvement in A1c levels was observed with minimal weight change and without increases in rates of hypoglycemia. The data were presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.

“The study is a testament to the safety of Levemir®, as patients were able to adjust their basal insulin dose on their own and achieve the same level of glycemic control as when guided by their doctor, while reducing the risk of hypoglycemia” said Luigi Meneghini, MD, MBA, Associate Professor of Clinical Medicine and the Director of the Eleanor and Joseph Kosow Diabetes Treatment Center at the Diabetes Research Institute, Miami, FL. “Since having Type 2 diabetes requires a great deal of self-management, these findings will help empower patients to work more closely as partners with their physician to take control of their insulin treatment. The potential of improved self-management is made possible by insulin analogs like Levemir®, which provide effective basal insulin coverage, and, as shown in this study, the added benefit of minimal weight change.”

The new data were obtained from the insulin detemir 303 Algorithm tested in a Randomized Clinical Trial: The US PREDICTIVE™ 303 Trial (Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation), which included 5,604 patients. The da
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/20/2009)...tCall/ -- Cyberonics, Inc. (Nasdaq: CYBX ) today ...utive Officer, and Greg Browne, Chief Financial Of...ay Health Care Conference in New York on Wednesday...e session and webcast will be audio only and no fo... host a webcast of the presentation live and by re...
(Date:11/19/2009).../ -- Warner Chilcott plc (Nasdaq: WCRX ) today an...condary offering of 20,000,000 of its ordinary sha... The selling shareholders include funds affiliated... J.P. Morgan Partners (advised by CCMP Capital) an...itutional investors and members of the Company,s s...
(Date:11/19/2009)...wswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. ...e presentation will be webcast live during the 21s...ednesday, December 2, 2009 at 9:00 a.m. Eastern Ti... York Palace Hotel in New York and will be present...,, To access the live presentation via the Web,...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Play it Straight with Swine Flu AA Travel Insurance Advises 53412 1Play it Straight with Swine Flu AA Travel Insurance Advises 53412 2Play it Straight with Swine Flu AA Travel Insurance Advises 53412 3Play it Straight with Swine Flu AA Travel Insurance Advises 53412 4Swine Flu Advice from Confused com 53410 1Swine Flu Advice from Confused com 53410 2Swine Flu Advice from Confused com 53410 3 Study finds increased sibling risk of obstructive sleep apnea in children 53408 1 Study finds increased sibling risk of obstructive sleep apnea in children 53408 2
...ference Call Scheduled for Friday, May 4, at 9:00 ...May 03, 2007 /PRNewswire-FirstCall/ --,Medivation,...and,moderate subgroups of Alzheimer,s disease pati...tudy of Dimebon showed that both,subgroups were im...ll five efficacy endpoints studied. , The mean dru...
...ts Homspera Shows Promise As an Adjuvant for Vacci...E, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- I...preliminary data,from its influenza vaccine adjuva...ar Inc. indicates Homspera elevates host,immune re...ystem.,These results are from an ongoing study, an...
Other Medicine Technology:Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 2Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 3Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 4Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 5IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 2IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 3IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 4
(Date:11/21/2009)... A regional initiative l...river blindness) in the Americas has substantially...ears, as evidenced by a 31% decrease in the number... in six endemic countries. Results were reported ...ociety of Tropical Medicine and Hygiene (ASTMH). ...
(Date:11/21/2009)..., 2009 Test Test Test Te...st Test Test Test Test Test,Test Test Test Test Te...st,Test Test Test Test Test Test Test Test Test Te...est More test More test More test More test,More t...est More test More,test More test , , Please i...
(Date:11/21/2009)...ive medical apparel company launches men,s lab coa... San Clemente, Calif. (PRWEB) November 21, 20... apparel, today announced the launch of its men,s ...leading international trade fair for the medical i...gurates its men,s collection with three varying la...
(Date:11/21/2009)... Hall, president and chief executive officer of th...he following statement regarding the inclusion of ...annual wellness for Medicare beneficiaries in &quo...uot; that was introduced last night: , ...09 -- Eric J. Hall, president and chief executive ...
(Date:11/21/2009)... Group ask whether there is a secret to ,alcohol r... London, UK (PRWEB) November 21, 200...hree of the adult UK population drinking enough al...ed liver disease*, it is hardly a surprise that ma...rammes and residential centres for help. However, ...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4
... the animals have lost the ability to replace thei... the ability of replacing the missing //leg with a...ow research teams of Salk Institute for Biological...ial for such regeneration may also exists innately...
...men boxers gathered here for the ongoing World Cha...the fact that they stand a chance //of rupturing t...ceiving. While some are simply after medals,...ird successive gold medal in the 46 kg at the Worl...
...reak of Norovirus has been reported in Royal Bourn...n the complete closure of wards 4,5,27 // and 28 t...at the virus has been contained in the ward areas....t patients in the hospital as a precautionary meas...
...ades, researchers have suspected a connection betw... (RA). Previous research has yielded widely varyin...// , partly because studies have used different di...al Meeting on Nov. 11 confirming that patients wit...
... researchers have produced a vaccine that activate... to attack cancerous cells. // During a clin...ersity of Nottingham discovered that when the vacc...r 15 issue of Clinical Cancer Research has carried...
...rious post-operative eye ailment that swept along ...aract-surgery unit in Scarborough Hospital, one of... The Hospital, which performs around 5,000 eye ... toxic anterior segment syndrome, or TASS. Moreov...
Other Medicine News:Health News:Limb Regeneration Exists Innately In All Vertebrates – Says Researc 2Health News:Limb Regeneration Exists Innately In All Vertebrates – Says Researc 3Health News:As these women box on, do they risk becoming mothers? 2Health News:As these women box on, do they risk becoming mothers? 3Health News:Study Examines Link Between Rheumatoid Arthritis and Chronic Lung Diseases 2Health News:A novel vaccine proves a shot in the arm for colorectal cancer patients 2Health News:Eye Surgeries Remain Cancelled Due To TASS Outbreak In Toronto 2
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: